ATE263237T1 - Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung - Google Patents

Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung

Info

Publication number
ATE263237T1
ATE263237T1 AT99201866T AT99201866T ATE263237T1 AT E263237 T1 ATE263237 T1 AT E263237T1 AT 99201866 T AT99201866 T AT 99201866T AT 99201866 T AT99201866 T AT 99201866T AT E263237 T1 ATE263237 T1 AT E263237T1
Authority
AT
Austria
Prior art keywords
libraries
efficient method
nucleic acids
gene functions
sample nucleic
Prior art date
Application number
AT99201866T
Other languages
English (en)
Inventor
Govert Schouten
Ronald Vogels
Abraham Bout
Es Helmuth Van
Original Assignee
Galapagos Genomics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics Nv filed Critical Galapagos Genomics Nv
Application granted granted Critical
Publication of ATE263237T1 publication Critical patent/ATE263237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
AT99201866T 1998-06-12 1999-06-11 Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung ATE263237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/097,239 US6413776B1 (en) 1998-06-12 1998-06-12 High throughput screening of gene function using adenoviral libraries for functional genomics applications

Publications (1)

Publication Number Publication Date
ATE263237T1 true ATE263237T1 (de) 2004-04-15

Family

ID=22262382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99201866T ATE263237T1 (de) 1998-06-12 1999-06-11 Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung

Country Status (10)

Country Link
US (3) US6413776B1 (de)
EP (1) EP1022335B1 (de)
JP (1) JP3672494B2 (de)
AT (1) ATE263237T1 (de)
AU (1) AU756605B2 (de)
CA (1) CA2301403C (de)
DE (1) DE69916005T2 (de)
MX (1) MXPA00012401A (de)
NZ (1) NZ508995A (de)
WO (1) WO1999064582A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766891A (en) * 1994-12-19 1998-06-16 Sloan-Kettering Institute For Cancer Research Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
KR100470180B1 (ko) * 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2000020555A2 (en) 1998-10-06 2000-04-13 Aarl Inc Transformation system in the field of filamentous fungal hosts: in chrysosporium
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
JP4303418B2 (ja) * 1997-10-24 2009-07-29 ライフ テクノロジーズ コーポレーション 組換え部位を有する核酸を使用する組換えクローニング
AU3548799A (en) * 1998-04-03 1999-10-25 Invitrogen Corporation Libraries of expressible gene sequences
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP2002535003A (ja) * 1999-01-29 2002-10-22 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ アポトーシスを誘導するｄｎａ配列の単離方法及び検出システム
US6642052B2 (en) * 1999-02-25 2003-11-04 National Research Council Of Canada Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1248856A2 (de) * 1999-12-23 2002-10-16 Xantos Biomedicine AG Screening-verfahren für nukleinsäuren
US6998263B2 (en) 2000-02-09 2006-02-14 Genvec, Inc. Methods of preparing and using a viral vector library
US7078501B2 (en) 2000-02-25 2006-07-18 Invitrogen Corporation Topoisomerase linker-mediated amplification methods
US7216113B1 (en) * 2000-03-24 2007-05-08 Symyx Technologies, Inc. Remote Execution of Materials Library Designs
KR20020026456A (ko) 2000-04-13 2002-04-10 에말파브 마크 아론 사상균에서 발현된 ｄｎａ 라이브러리의 고산출량 스크리닝
WO2003036265A2 (en) * 2001-10-26 2003-05-01 Virtual Arrays, Inc. Assay systems with adjustable fluid communication
AU2001252766A1 (en) * 2000-04-26 2001-11-07 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
ATE315086T1 (de) 2000-08-21 2006-02-15 Invitrogen Corp Methoden und reagenzien für molekulares klonieren
US7198924B2 (en) * 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
JP2004520047A (ja) * 2000-12-08 2004-07-08 インヴィトロジェン コーポレーション 組換え型核酸分子を迅速に作製するための組成物と方法
EP1227157A1 (de) * 2001-01-19 2002-07-31 Galapagos Genomics B.V. Swap/Gegenselektion: eine schnelles Klonierungsverfahren
CA2441209C (en) * 2001-01-25 2012-11-13 Virxsys Corporation Methods and compositions for identifying gene function
WO2002070744A2 (en) * 2001-03-07 2002-09-12 Galapagos Genomics B.V. Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
US20040132008A1 (en) * 2002-04-30 2004-07-08 Doranz Benjamin J Elucidation of gene function
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
AU2002315157A1 (en) * 2001-06-14 2003-01-02 Anadys Pharmaceuticals, Inc. Methods of screening for ligands of target molecules
EP1273667A1 (de) * 2001-07-04 2003-01-08 Galapagos Genomics N.V. Hochdurchsatzidentifizierung von Angiogenese Modulatoren
ES2609014T3 (es) 2001-07-12 2017-04-18 University Of Massachusetts Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
EP1417306A2 (de) * 2001-08-10 2004-05-12 Xantos Biomedicine AG Hochdurchsatz dna-isolierung und -transfektion zur analyse der funktion von genen bzw. genprodukten
WO2003018799A2 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US20080187949A1 (en) * 2001-10-26 2008-08-07 Millipore Corporation Multiplexed assays of cell migration
US7381375B2 (en) 2001-10-26 2008-06-03 Millipore Corporation Assay systems with adjustable fluid communication
JP2005514959A (ja) * 2002-01-24 2005-05-26 エコピア バイオサイエンシーズ インク 微生物から二次代謝産物を同定するための方法、システム及び情報リポジトリ
DK1511843T3 (da) * 2002-06-07 2006-07-24 Sophion Bioscience As Screeningsmetoder
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
EP2314629B2 (de) 2002-07-18 2022-11-16 Merus N.V. Rekombinante Herstellung von Mischungen aus Aantikörpern
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
JP4287633B2 (ja) * 2002-09-18 2009-07-01 独立行政法人科学技術振興機構 オルガネラ局在タンパク質の解析方法と解析材料
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20080207465A1 (en) * 2002-10-28 2008-08-28 Millipore Corporation Assay systems with adjustable fluid communication
WO2004046353A1 (ja) * 2002-11-21 2004-06-03 Genomidea Inc. 所望の機能的性質を有する核酸の単離方法およびそのためのキット
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005001133A2 (en) * 2003-06-03 2005-01-06 Collateral Therapeutics, Inc. Compositions and methods for high throughput construction and functional analysis of expression libraries
US20050059083A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company High throughput method to identify ligands for cell attachment
US20050060100A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company Computer software and algorithms for systems biologically linked to cellular phenotype
US8304189B2 (en) * 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
AU2003300239A1 (en) * 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
EP1743032A4 (de) * 2004-04-15 2007-09-05 Allied Biotech Inc Verfahren und vorrichtung zum nachweis von virusinfektionen
SI1745295T1 (sl) 2004-04-20 2011-01-31 Galapagos Nv Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta
GB0410105D0 (en) * 2004-05-06 2004-06-09 Amersham Biosciences Uk Ltd Method for characterising compounds
WO2005121778A2 (en) 2004-06-14 2005-12-22 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
US8680252B2 (en) 2006-12-10 2014-03-25 Dyadic International (Usa), Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
HRP20140405T1 (hr) 2007-06-20 2014-06-20 Galapagos N.V. Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova
CA2736661A1 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
CL2009001064A1 (es) 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
WO2010029118A1 (en) 2008-09-11 2010-03-18 Biofocus Dpi B.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TW201120043A (en) 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
WO2016069591A2 (en) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, methods and use of synthetic lethal screening
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (de) 2014-12-19 2025-10-22 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
CR20180519A (es) 2016-03-31 2019-03-05 Neon Therapeutics Inc Neoantígenos y métodos de su uso
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
EP3336169A1 (de) * 2016-12-15 2018-06-20 Institut Polytechnique de Grenoble Robotisches verfahren zum beschichten einer multiwellplatte durch einen mehrschichtigen polyelektrolytfilm
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
WO2019136169A1 (en) * 2018-01-04 2019-07-11 Arizona Board Of Regents On Behalf Of Arizona State University Versatile amplicon single-cell droplet sequencing-based shotgun screening platform to accelerate functional genomics
US12612644B2 (en) 2018-08-10 2026-04-28 Regenxbio Inc. Scalable method for recombinant AAV production
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN119932113A (zh) 2019-02-22 2025-05-06 生命技术公司 用于腺相关病毒产生的悬浮系统
CA3148079A1 (en) 2019-07-23 2021-01-28 Janssen Biotech, Inc. Synthetic genetic elements for biomanufacture of adeno-associated viruses
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
JP7854946B2 (ja) 2020-05-26 2026-05-07 ディオニス セラピューティクス インコーポレイテッド 核酸人工ミニプロテオームライブラリー
CA3202176A1 (en) 2020-12-14 2022-06-23 Michael Steven ROONEY Tissue-specific antigens for cancer immunotherapy
EP4426829A1 (de) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologisch ausgewählte bibliotheken künstlicher miniproteome von nukleinsäuren
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
CA2053187A1 (en) 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CN1115414C (zh) 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 用于基因治疗的病毒载体
US5401744A (en) 1993-10-04 1995-03-28 Bristol-Myers Squibb Company Useful hemi-hydrate form of a cerebral function enhancing agent
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US6204052B1 (en) 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
KR100470180B1 (ko) * 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU1695197A (en) * 1996-01-05 1997-08-01 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US6153380A (en) 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
DE69831598D1 (de) 1997-12-19 2005-10-20 Hk Pharmaceuticals Inc Nicht-bakterielles klonierungssystem zur verabreichung und expression von nukleinsäuren
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Also Published As

Publication number Publication date
AU756605B2 (en) 2003-01-16
DE69916005T2 (de) 2004-09-09
EP1022335A1 (de) 2000-07-26
WO1999064582A3 (en) 2000-04-06
AU4294799A (en) 1999-12-30
CA2301403C (en) 2009-01-06
US7029848B2 (en) 2006-04-18
US20030027170A1 (en) 2003-02-06
MXPA00012401A (es) 2003-07-14
WO1999064582A2 (en) 1999-12-16
NZ508995A (en) 2003-12-19
US6413776B1 (en) 2002-07-02
EP1022335B1 (de) 2004-03-31
DE69916005D1 (de) 2004-05-06
JP3672494B2 (ja) 2005-07-20
CA2301403A1 (en) 1999-12-16
JP2002526031A (ja) 2002-08-20
US6340595B1 (en) 2002-01-22

Similar Documents

Publication Publication Date Title
DE69916005D1 (de) Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung
DE60039037D1 (de) Methode zur direkten sequenzierung von nukleinsäuren
WO2004083225A3 (fr) Biopuces a sondes et leurs methodes d’utilisation
ATE118549T1 (de) Verfahren zur synthese von ribonukleinsäure (rns).
DE68921315D1 (de) Verfahren zur Herstellung synthetischer Oligonukleotide, die spezifisch an Bestimmungsstellen auf Duplex-DNA-Molekülen binden durch Formen eines kolinearen Triplex, die synthetischen Oligonukleotide und Verfahren zu ihrer Herstellung.
ATE343586T1 (de) Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung
ATE141956T1 (de) Verfahren zur vervielfältigung von nukleinsäuresequenzen
DE60127162D1 (de) Massives Parallelverfahren zur Dekodierung von DNA und RNA
ATE545710T1 (de) Verfahren zur vervielfältigung von nukleinsäuren
DE69034061D1 (de) Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken
ATE282717T1 (de) Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
ATE377074T1 (de) Methode zur bereitstellung von dna sequenzen
EP1012161A4 (de) Hochempfindliche polymerasen und ihre verwendungen
EP1480155A3 (de) Informationsverarbeitungsanlage, Informationsverarbeitungsverfahren, Speichermedium und Programm
AU2003291610A1 (en) Method to generate or determine nucleic acid tags corresponding to the terminal ends of dna molecules using sequences analysis of gene expression (terminal sage)
WO2000022171A3 (en) Systems and methods for sequencing by hybridization
ATE278808T1 (de) Verfahren zur charakterisierung von nukleinsäurefragmenten
ATE211180T1 (de) Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit
EP1335027A4 (de) Quantifizierungsverfahren für die genetische modifikation und standardmolekül zur verwendung darin
DE59410068D1 (de) Verfahren zur spezifischen Klonierung von Nukleinsäuren
ATE144557T1 (de) Nucleinsäure-proben und verfahren zum nachweis von giardia lamblia
ATE317123T1 (de) Reaktiver träger zur bestimmung von dna fragmenten
DE50014875D1 (de) Verfahren zum herstellen eines rekombinanten proteins
PT778347E (pt) Proteina ligante a atp e acidos nucleicos com propriedade de helicase e de atpase
WO2000021984A3 (en) Nucleic acids encoding human cide-b protein and polymorphic markers thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
EEFA Change of the company name